Pesquisar
Leap Therapeutics Inc
LPTXAdicionar à lista de desejos
2.050USD
0.0000.00%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
68.57MValor de mercado
PerdaP/L TTM
Mais detalhes de Leap Therapeutics Inc Empresa
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Informações de Leap Therapeutics Inc
Código da empresaLPTX
Nome da EmpresaCypherpunk Technologies Inc
Data de listagemJan 24, 2017
CEOOnsi (Douglas E)
Número de funcionários52
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 24
Endereço47 Thorndike Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02142
Telefone16172524343
Sitehttps://www.leaptx.com/
Código da empresaLPTX
Data de listagemJan 24, 2017
CEOOnsi (Douglas E)
Executivos da empresa Leap Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
Perguntas frequentes
Quem são os cinco principais acionistas de Leap Therapeutics Inc?
Os cinco principais acionistas de Leap Therapeutics Inc são: Dr. James H. Cavanaugh, Ph.D.
Quantas instituições possuem ações da Leap Therapeutics Inc (LPTX)?
Em 2026Q1, 114 instituições possuíam ações da Leap Therapeutics Inc, com valor de mercado aproximado de 11.73M, representando 12.01% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -9047212.00.